Multisystem inflammatory syndrome in children treated with intravenous immunoglobulin monotherapy: a single-center retrospective study

IF 0.5 Q4 PEDIATRICS

Egyptian Pediatric Association Gazette Pub Date : 2024-09-16 DOI:10.1186/s43054-024-00309-8

Murat Kangin, Asuman Akar, Mehmet Nur Talay, Ozlem Gul, Muhammed Tas, Ayten Semdinoglu, Caner Alparslan, Sevgen Tanir Basaranoglu, Nurhayat Yakut

{"title":"Multisystem inflammatory syndrome in children treated with intravenous immunoglobulin monotherapy: a single-center retrospective study","authors":"Murat Kangin, Asuman Akar, Mehmet Nur Talay, Ozlem Gul, Muhammed Tas, Ayten Semdinoglu, Caner Alparslan, Sevgen Tanir Basaranoglu, Nurhayat Yakut","doi":"10.1186/s43054-024-00309-8","DOIUrl":null,"url":null,"abstract":"Multisystem inflammatory syndrome in children (MIS-C) is one of the complications of SARS-CoV-2 infection. This study aims to evaluate the clinical and laboratory characteristics, as well as treatment results, of MIS-C patients who received intravenous immunoglobulin (IVIG) monotherapy. This retrospective study included patients diagnosed with MIS-C. Demographic data, organ involvements at the admission, laboratory evaluations for diagnosis, treatment, and follow-up were recorded. We evaluated outcomes by the length of the intensive care unit stay, the total hospitalization period, complications, and mortality. A total of 95 patients diagnosed with MIS-C were evaluated. The mean age was 118.8 (± 52.5) months. 76.8% of the patients had four or more organ systems involved. Seventy-nine patients (83%) were hospitalized in the pediatric intensive care unit (PICU) for a mean of 4.59 days. Seventy-seven (81%) patients received IVIG. A second dose of IVIG was administered to 66.3% of patients. All patients received vitamin D and C supplementation. Six patients who had cardiac involvement or cerebral infarction were treated with plasmapheresis. No patients received steroids. There was no mortality at the end of the follow-up. Favorable outcomes may be obtained with IVIG monotherapy in MIS-C patients. More clinical trials are needed to establish the role of supportive treatments like vitamin D and C in MIS-C management.","PeriodicalId":43064,"journal":{"name":"Egyptian Pediatric Association Gazette","volume":null,"pages":null},"PeriodicalIF":0.5000,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Egyptian Pediatric Association Gazette","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s43054-024-00309-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PEDIATRICS","Score":null,"Total":0}

引用次数: 0

Abstract

Multisystem inflammatory syndrome in children (MIS-C) is one of the complications of SARS-CoV-2 infection. This study aims to evaluate the clinical and laboratory characteristics, as well as treatment results, of MIS-C patients who received intravenous immunoglobulin (IVIG) monotherapy. This retrospective study included patients diagnosed with MIS-C. Demographic data, organ involvements at the admission, laboratory evaluations for diagnosis, treatment, and follow-up were recorded. We evaluated outcomes by the length of the intensive care unit stay, the total hospitalization period, complications, and mortality. A total of 95 patients diagnosed with MIS-C were evaluated. The mean age was 118.8 (± 52.5) months. 76.8% of the patients had four or more organ systems involved. Seventy-nine patients (83%) were hospitalized in the pediatric intensive care unit (PICU) for a mean of 4.59 days. Seventy-seven (81%) patients received IVIG. A second dose of IVIG was administered to 66.3% of patients. All patients received vitamin D and C supplementation. Six patients who had cardiac involvement or cerebral infarction were treated with plasmapheresis. No patients received steroids. There was no mortality at the end of the follow-up. Favorable outcomes may be obtained with IVIG monotherapy in MIS-C patients. More clinical trials are needed to establish the role of supportive treatments like vitamin D and C in MIS-C management.

查看原文本刊更多论文

静脉注射免疫球蛋白单药治疗儿童多系统炎症综合征：一项单中心回顾性研究

儿童多系统炎症综合征（MIS-C）是 SARS-CoV-2 感染的并发症之一。本研究旨在评估接受静脉注射免疫球蛋白（IVIG）单一疗法的儿童多系统炎症综合征患者的临床和实验室特征以及治疗效果。这项回顾性研究纳入了确诊为 MIS-C 的患者。研究记录了患者的人口统计学数据、入院时器官受累情况、实验室诊断评估、治疗和随访情况。我们根据重症监护室住院时间、总住院时间、并发症和死亡率对结果进行了评估。共对 95 名确诊为 MIS-C 的患者进行了评估。平均年龄为 118.8 (± 52.5) 个月。76.8%的患者涉及四个或更多器官系统。79名患者（83%）在儿科重症监护室（PICU）住院治疗，平均住院时间为4.59天。77名患者（81%）接受了 IVIG 治疗。66.3%的患者接受了第二剂 IVIG 治疗。所有患者都补充了维生素 D 和 C。六名心脏受累或脑梗塞患者接受了血浆置换治疗。没有患者接受类固醇治疗。随访结束时没有出现死亡病例。对 MIS-C 患者进行 IVIG 单药治疗可能会取得良好的疗效。需要进行更多的临床试验，以确定维生素 D 和 C 等辅助治疗在 MIS-C 治疗中的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Egyptian Pediatric Association Gazette PEDIATRICS-

自引率

0.00%

发文量

审稿时长

9 weeks

期刊介绍： The Gazette is the official journal of the Egyptian Pediatric Association. The main purpose of the Gazette is to provide a place for the publication of high-quality papers documenting recent advances and new developments in both pediatrics and pediatric surgery in clinical and experimental settings. An equally important purpose of the Gazette is to publish local and regional issues related to children and child care. The Gazette welcomes original papers, review articles, case reports and short communications as well as short technical reports. Papers submitted to the Gazette are peer-reviewed by a large review board. The Gazette also offers CME quizzes, credits for which can be claimed from either the EPA website or the EPA headquarters. Fields of interest: all aspects of pediatrics, pediatric surgery, child health and child care. The Gazette complies with the Uniform Requirements for Manuscripts submitted to biomedical journals as recommended by the International Committee of Medical Journal Editors (ICMJE).